Publications 2010

 

Boulet T, Pavie J, Charreau I, Braun J, Reynes J, Morlat P, Piroth L, Spire B, Molina JM, Aboulker JP and the EASIER ANRS 138 study group.Impact on Health-related Quality of life of a switch from Enfuvirtide to Raltegravir among Multidrug-Resistant HIV-1 Infected Patients: A Randomized Open-Label Trial (Easier - ANRS 138). HIV Clin Trials 2010;11(5):283-293. Lien PubMed

Gibb DM, Castro H, Compagnucci A, Klein N, Lallemant M, Lyall H, Nadal D, Ananworanich J, Babiker A, Bunupuradah T, Darbyshire JH, De Rossi A, Gonzalez MI Tome, Harper L, Kanjavanit S, Marczynska M, Mofenson L, Monpoux F, Moye J, Munoz-Fernandez MA, Ngo-Giang-Huong N, Niehues T, Saidi Y, Walker AS, U.Wintergerst U and Giaquinto C. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS.2010 Jan 16;24(2):231-41. Lien PubMed

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, and Taburet AM. Influence of Alpha-1 glycoprotein acid concentrations and variants on Atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 Trial. Antimicrobial Agents and Chemother 2010, 54:614-619.Lien PubMed

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R and NEAT-WP4. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clin Trials 2010, 7:19-35.
Lien PubMed

Barau C, Delaugerre C, Braun J, De Castro N, Furlan V, Charreau I, Gérard L, Lascoux-Combe C, Molina JM, Taburet AM. High Concentration of Raltegravir in Semen of HIV-infected Men: a sub-study of the EASIER-ANRS 138 trial. Antimicrob. Agents Chemother 2010, 54(2):937-9.
Lien PubMed

Durier C*, Salmon-Céron D*, Desaint C, Cuzin L, Surenaud M, Ben Hamouda N, Lelièvre J-D, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker J-P, Lévy Y, Launay O, for the ANRS VAC18 trial group.Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS.2010 Sep 10;24 .
Lien PubMed

Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vézinet F, and Descamps D on behalf of the ANRS 127 Study Group. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients. Antimicrob Agents Chemother 2010, 54 (7):2910-19.
Lien PubMed

Jacqz-Aigrain E, Harrison L, Zhao W, Compagnucci A, Castro H (née Green), Farrelly L, Saïdi Y, Hamadache D, Welch S, Wintergerst U, Forcat S, Hadjou G, Firtion G, Snowden W, Giaquinto C, Gibb D and Burger D, for the Paediatric European Network for Treatment of AIDS (PENTA).Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 2-36 months. Antiviral Ther 2010, 15:297-305.
Lien PubMed

Fontas E, Kousignian I, Pradier C, Isabelle Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D, on behalf of FHDH ANRS CO4.IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy-results from the ANRS CO4 cohort, ANRS CO14. JAntimicrob Chemother 2010, 65(10):2215-23. Epub 2010 Aug. 11.
Lien PubMed

Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Ben Hamouda N, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O, for the ANRS VAC18 trial group.Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010, 24:2211-23.
Lien PubMed

Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F, the ANRS 138 study group.Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS
2010, 24:2391-95. Lien PubMed